TScan Therapeutics TCRX
NASDAQ TCRX
$0.32 +0.00 (+0.95%)
At close: Oct 1, 2026 · 4:00 PM EDT

TScan Therapeutics (TCRX) EBITDA Margin (2020 - 2026)

Updated

TScan Therapeutics (TCRX) recorded EBITDA Margin of -2834.82% in Q2 2026, down 1600.92 percentage points from -1233.91% a year earlier but up 61.92 percentage points from the prior quarter.

Analysis

TScan Therapeutics (TCRX) EBITDA Margin (2020 - 2026) Analysis & Trends

On a TTM basis, TScan Therapeutics' EBITDA Margin came in at -1654.62% as of Jun 30, 2026, up 372.72 percentage points year-over-year; for FY2025, it was -1287.29%, up 3354.79 percentage points from FY2024.

  • Annual EBITDA Margin has a five-year change of +1019.90 percentage points (FY2020 to FY2025).
  • Across earlier years, EBITDA Margin came in at -4642.08% in FY2024 (-4223.73 pp), -418.35% in FY2023 (+36.30 pp), -454.64% in FY2022 (-7.54 pp) and -447.11% in FY2021 (+1860.08 pp).
  • Quarterly EBITDA Margin has ranged from -6156.34% in Q2 2024 to -278.42% in Q4 2023 over the past five years.
  • On a year-over-year basis, EBITDA Margin rose in four of the last eight quarters, with an average year-over-year change of +535.24 percentage points.
  • Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 4922.44 percentage points in Q2 2025, against a drop of 5415.75 percentage points in Q2 2024 at the low end.
  • Per Business Quant, the preceding three quarters came in at -2896.74% (Q1 2026), -901.25% (Q4 2025) and -1445.04% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 35.95%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 49.01%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 6.02%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 33.11%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 46.01%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -124.26%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 39.10%
10 TScan Therapeutics 40.28 Mn 40.28 Mn - -2,834.82%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2,834.82%
Mar 31, 2026 -2,896.74%
Dec 31, 2025 -901.25%
Sep 30, 2025 -1,445.04%
Jun 30, 2025 -1,233.91%
Mar 31, 2025 -1,638.51%
Dec 31, 2024 -5,413.68%
Sep 30, 2024 -3,011.92%
Jun 30, 2024 -6,156.34%
Mar 31, 2024 -5,321.38%
Dec 31, 2023 -278.42%
Sep 30, 2023 -603.60%
Jun 30, 2023 -740.60%
Mar 31, 2023 -312.27%
Dec 31, 2022 -554.60%
Sep 30, 2022 -455.75%
Jun 30, 2022 -346.13%
Mar 31, 2022 -495.47%
Dec 31, 2021 -457.60%
Sep 30, 2021 -613.02%
API Access

TScan Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TCRX&period=max&api_key=YOUR_API_KEY